E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Refractory wtKRAS metastatic colorectal cancer |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10052362 |
E.1.2 | Term | Metastatic colorectal cancer |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Non Progression rate at 6 months |
|
E.2.2 | Secondary objectives of the trial |
•Objective response rate based on RECIST v1.1,
•Safety and tolerability of afatinib and cetuximab combo,
•Progression Free survival (PFS)
•Overall survival
|
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Ancillary translational study:
Although some studies have suggested the existence of predictive factors of response: tumor size, concomitant chemotherapy, the biological factors determining tumor response are not known.
The objective of the biological study is to identify, within the framework of the prospective randomized clinical trial, the biological factors predictive of tumor response, toxicity and the metastatic risk (with genomics).
This study of biological factors which are predictive of the response to treatment will be undertaken by centers willing to participate.
1-Molecular analyses on tumor DNA
2-Fluorescent in situ hybridization (FISH) on tumor tissues
3-Intratumoral protein expression by immunohistochemistry (IHC)
4-Analysis of germline polymorphisms |
|
E.3 | Principal inclusion criteria |
1.Metastatic colorectal cancer expressing the wtKRAS status
2.No previous EGFR targeted therapy.
3.Must have failed a prior regimen containing irinotecan for metastatic disease and a prior regimen containing oxaliplatin for metastatic disease
4.Must have previously received a thymidylate synthase inhibitor (eg, fluorouracil, capecitabine, raltitrexed, or fluorouracil-uracil) at any point for treatment of colorectal cancer (CRC)
5.Life expectancy of at least 3 months.
6.Patient with ECOG ≤ 1
7.Patients aged ≥ 18.
8.Patient with measurable lesions according to RECIST criteria (version 1.1) with spiral CT scan and defined as ≥ 10 mm in longest diameter and 2X the slice thickness for extra nodal lesions and/or > 15 mm in short axis diameter for nodal lesions
9.Patient able to receive adequate oral nutrition of ≥ 1500 calories per day and free of significant nausea and vomiting
10.Patient with adequate organ function:
•Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
•Haemoglobin ≥ 9 g/dL
•Platelets (PTL) ≥ 100 x 109/L
•AST/ALT ≤ 2.5 x ULN (≤ 5 x ULN in case of liver metastases)
•GammaGT < 3 x ULN (< 5 x ULN in case of liver involvement)
•Bilirubin ≤ 1.5 x ULN
•Creatinine clearance ≥ 50 mL/min (Cockcroft and Gault formula)
11.Adequate contraception if applicable.
12.Ability to take oral medication in the opinion of the investigator.
13.Patient able and willing to comply with study procedures as per protocol
14.Patient able to understand and willing to sign and date the written voluntary informed consent form at screening visit prior to any protocol-specific procedures
15.Patient affiliated to a social security regimen
|
|
E.4 | Principal exclusion criteria |
1.Previous EGFR targeted therapy.
2.Mutant KRAS status
3.Prior severe reaction to a monoclonal antibody
4.Clinically relevant cardiovascular abnormalities, as judged by the investigator, such as, but not limited to, uncontrolled hypertension, congestive heart failure NYHA classification > III, unstable angina, myocardial infarction within six months prior to randomisation, or poorly controlled arrhythmia
5.Cardiac left ventricular dysfunction with resting ejection fraction of less than institutional lower limit of normal (if no lower limit of normal is defined in the institution, the lower limit is 50%)
6.Symptomatic brain metastases requiring treatment
7.Major surgery within 28 days or minor surgery within 14 days of the start of the study treatment
8.Radiotherapy less than two weeks prior to the start of the study treatment
9.Systemic chemotherapy, hormonal therapy, immunotherapy ≤ 28 days before study treatment
10.No major comorbidity that may preclude the delivery of treatment or active infection (HIV or chronic hepatitis B or C) or uncontrolled diabetes.
11.Concomitant occurrence of another cancer, or history of cancer within the past five years except in situ carcinoma of the cervix treated or basal cell carcinoma or squamous cell carcinoma.
12.Known pre-existing interstitial lung disease
13.Significant or recent acute gastrointestinal disorders with diarrhea as a major symptom e.g., Crohn’s disease, malabsorption, or CTCAE grade >2 diarrhea of any etiology
14.Pregnant woman or lactating woman.
15.Persons deprived of liberty or under guardianship.
16.Psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint non progression rate will be presented by the percentage of patients without progression at 6 months with the 95% confidence interval. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Quality of life (QLQ C30 + QLQ-CR29) |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 20 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |